Could a drug combo boost the immune system against kidney cancer?
NCT ID NCT05733715
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial is testing whether giving the immunotherapy drug pembrolizumab (Keytruda) alone or with lenvatinib (Lenvima) before and after kidney cancer surgery can strengthen the immune system's attack on the tumor. About 30 adults with high-risk kidney cancer will receive the drugs and have their immune cells measured. The goal is to see if these treatments can reduce the amount of cancer left after surgery and help prevent recurrence.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
pembrolizumab (Keytruda) and lenvatinib (Lenvima)
What this could lead to
If it works, this could point toward a way to shrink kidney tumors before surgery and reduce the chance of cancer coming back.
What could go wrong
This is a very early, small pilot study (30 people) testing immune markers, not yet proven to improve survival. Side effects from the drugs may occur.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Abramson Cancer Center at University of Pennsylvania
RECRUITINGPhiladelphia, Pennsylvania, 19104, United States